v3.26.1
Cover
Jul. 20, 2026
Entity Addresses [Line Items]  
Document Type 8-K/A
Amendment Flag true
Amendment Description As previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on July 20, 2026 (the “Original Form 8-K”), on that same day (the “Closing Date”), after obtaining the requisite shareholder approval and satisfying the closing conditions, Niki BioSolutions, Inc. (formerly known as Aptorum Group Limited) (the “Company”) consummated its previously announced merger (the “Closing”) pursuant to that certain Agreement and Plan of Merger on July 14, 2025, (the “Merger Agreement”), between Aptorum and DiamiR Biosciences Corp., a Delaware corporation (“DiamiR”), pursuant to which, among other matters, Aptorum was to form a direct, wholly owned subsidiary in the state of Delaware (“Merger Sub”).
Document Period End Date Jul. 20, 2026
Entity File Number 001-38764
Entity Registrant Name Niki BioSolutions, Inc.
Entity Central Index Key 0001734005
Entity Tax Identification Number 42-3265309
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 116 Village Boulevard
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code 609
Local Phone Number 951-2222
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol NIKI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Former Address [Member]  
Entity Addresses [Line Items]  
Entity Registrant Name Aptorum Group Limited
Entity Address, Address Line One 17 Hanover Square
Entity Address, City or Town London
Entity Address, Country GB
Entity Address, Postal Zip Code W1S 1BN